US EditionPublished • loading... • Updated
Trump administration announces 15 new drugs for Medicare price negotiation program
The third Medicare negotiation round includes 15 drugs covering diabetes, HIV, and arthritis, with savings targeting $27 billion in spending, CMS said.
- On Tuesday, the Trump administration announced the next 15 drugs for Medicare price negotiations, marking the first year Medicare Part B medicines are eligible as the government met its Feb. 1 deadline.
- The negotiations stem from the Inflation Reduction Act of 2022, which gave CMS authority to select high‑spend drugs based on statutory criteria, including being 7 or 11 years post‑FDA approval and lacking generics, for about $27 billion in Medicare Part B and Part D spending in the past year.
- Notable entries range from diabetes medicines to cancer therapies and include Trulicity , Biktarvy , Botox and Xeljanz , covering diabetes, HIV, arthritis, cancer and autoimmune diseases.
- Companies have until Feb. 28 to decide on participation, CMS said Tradjenta will undergo renegotiation, and shares of Gilead, Eli Lilly, AbbVie, Johnson & Johnson, Pfizer and Bristol Myers rose nearly 2%.
- Cumulatively the program could yield significant taxpayer relief as this third round brings 40 drugs total and follows 36% savings on 15 drugs starting in 2027, about $8.5 billion.
Insights by Ground AI
86 Articles
86 Articles
Botox, Trulicity, and 13 Other Drugs Selected for Medicare Price Negotiation
(MedPage Today) -- The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers for Medicare & Medicaid...
·New York, United States
Read Full Article
Associated Press News+72 Reposted by 72 other sources
Trump administration announces 15 new drugs for Medicare price negotiation program
The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers.
·United States
Read Full Article
Coverage Details
Total News Sources86
Leaning Left11Leaning Right6Center57Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
15%
C 77%
Factuality
To view factuality data please Upgrade to Premium
